|Titre :||Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness (2014)|
|Auteurs :||G. J. MACARTHUR ; E. VAN VELZEN ; N. E. PALMATEER ; J. KIMBER ; A. PHARRIS ; V. HOPE ; A. TAYLOR ; K. ROY ; E. ASPINALL ; D. GOLDBERG ; T. RHODES ; D. HEDRICH ; M. SALMINEN ; M. HICKMAN ; S. J. HUTCHINSON|
|Type de document :||Article : Périodique|
|Dans :||International Journal of Drug Policy (Vol.25, n°1, January 2014)|
|Article en page(s) :||34-52|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASESALLE DE CONSOMMATION A MOINDRE RISQUE ; HEPATITE ; VIH ; USAGER ; INJECTION ; INTERVENTION ; EFFICACITE ; REDUCTION DES RISQUES ; CONDUITE A RISQUE ; TRAITEMENT DE MAINTENANCE ; ECHANGE DE SERINGUES ; CONTAMINATION
BACKGROUND: Injecting drug use is a major risk factor for the acquisition and transmission of HIV and Hepatitis C virus (HCV). Prevention of these infections among people who inject drugs (PWID) is critical to reduce ongoing transmission, morbidity and mortality.
METHODS: A review of reviews was undertaken involving systematic literature searches of Medline, Embase, CINAHL, PsychINFO, IBSS and the Cochrane Library (2000-2011) to identify English language reviews regarding the effectiveness of harm reduction interventions in relation to HIV transmission, HCV transmission and injecting risk behaviour (IRB). Interventions included needle and syringe programmes (NSP); the provision of injection paraphernalia; opiate substitution treatment (OST); information, education and counselling (IEC); and supervised injecting facilities (SIFs). Reviews were classified into 'core' or 'supplementary' using critical appraisal criteria, and the strength of review-level evidence was assessed.
RESULTS: Twelve core and thirteen supplementary reviews were included. From these reviews we identified: (i) for NSP: tentative review-level evidence to support effectiveness in reducing HIV transmission, insufficient review-level evidence relating to HCV transmission, but sufficient review-level evidence in relation to IRB; (ii) for OST: sufficient review-level evidence of effectiveness in relation to HIV transmission and IRB, but tentative review-level evidence in relation to HCV transmission; (iii) for IEC, the provision of injection paraphernalia and SIFs: tentative review-level evidence of effectiveness in reducing IRB; and either insufficient or no review-level evidence for these interventions in relation to HIV or HCV transmission.
CONCLUSION: Review-level evidence indicates that harm reduction interventions can reduce IRB, with evidence strongest for OST and NSP. However, there is comparatively little review-level evidence regarding the effectiveness of these interventions in preventing HCV transmission among PWID. Further studies are needed to assess the effectiveness and impact of scaling up comprehensive packages of harm reduction interventions to minimise HIV and HCV transmission among PWID.
|Domaine :||Drogues illicites / Illicit drugs|
|Sous-type de document :||Revue de la littérature / Literature review|
|Affiliation :||School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK|